Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 5201098, 8 pages
https://doi.org/10.1155/2017/5201098
Review Article

From Humoral Theory to Performant Risk Stratification in Kidney Transplantation

1Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France
2Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
3Department of Transplant Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
4Kidney Transplant Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

Correspondence should be addressed to C. Lefaucheur

Received 20 October 2016; Accepted 15 December 2016; Published 2 January 2017

Academic Editor: Junchao Cai

Copyright © 2017 C. Lefaucheur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Patel and P. I. Terasaki, “Significance of the positive crossmatch test in kidney transplantation,” New England Journal of Medicine, vol. 280, no. 14, pp. 735–739, 1969. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Nankivell and D. R. Kuypers, “Diagnosis and prevention of chronic kidney allograft loss,” The Lancet, vol. 378, no. 9800, pp. 1428–1437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Sellarés, D. G. de Freitas, M. Mengel et al., “Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence,” American Journal of Transplantation, vol. 12, no. 2, pp. 388–399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. P. I. Terasaki, “Humoral theory of transplantation,” American Journal of Transplantation, vol. 3, no. 6, pp. 665–673, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. I. Terasaki, “A personal perspective: 100-year history of the humoral theory of transplantation,” Transplantation, vol. 93, no. 8, pp. 751–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. I. Terasaki and M. Ozawa, “Predicting kidney graft failure by HLA antibodies: a prospective trial,” American Journal of Transplantation, vol. 4, no. 3, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. B. D. Tait, C. Süsal, H. M. Gebel et al., “Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation,” Transplantation, vol. 95, no. 1, pp. 19–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Djamali, D. B. Kaufman, T. M. Ellis, W. Zhong, A. Matas, and M. Samaniego, “Diagnosis and management of antibody-mediated rejection: current status and novel approaches,” American Journal of Transplantation, vol. 14, no. 2, pp. 255–271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Haas, B. Sis, L. C. Racusen et al., “Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions,” American Journal of Transplantation, vol. 14, no. 2, pp. 272–283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. R. Tambur, N. D. Herrera, K. M. K. Haarberg et al., “Assessing antibody strength: comparison of MFI, C1q, and titer information,” American Journal of Transplantation, vol. 15, no. 9, pp. 2421–2430, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Viglietti, A. Loupy, D. Vernerey et al., “Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss,” Journal of the American Society of Nephrology, 2016. View at Publisher · View at Google Scholar
  12. A. Konvalinka and K. Tinckam, “Utility of HLA antibody testing in kidney transplantation,” Journal of the American Society of Nephrology, vol. 26, no. 7, pp. 1489–1502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Schnaidt, C. Weinstock, M. Jurisic, B. Schmid-Horch, A. Ender, and D. Wernet, “HLA antibody specification using single-antigen beads—a technical solution for the prozone effect,” Transplantation, vol. 92, no. 5, pp. 510–515, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Schwaiger, M. Wahrmann, G. Bond, F. Eskandary, and G. A. Böhmig, “Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads,” Transplantation, vol. 97, no. 12, pp. 1279–1285, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Visentin, M. Vigata, S. Daburon et al., “Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays,” Transplantation, vol. 98, no. 6, pp. 625–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. R. Tambur, D. Glotz, N. D. Herrera et al., “Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?” Human Immunology, vol. 77, no. 8, pp. 624–630, 2016. View at Publisher · View at Google Scholar
  17. M. Wahrmann, M. Exner, H. Regele et al., “Flow cytometry based detection of HLA alloantibody mediated classical complement activation,” Journal of Immunological Methods, vol. 275, no. 1-2, pp. 149–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Calp-Inal, M. Ajaimy, M. L. Melamed et al., “The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation,” Kidney International, vol. 89, no. 1, pp. 209–216, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Chin, G. Chen, F. Sequeria et al., “Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients,” Journal of Heart and Lung Transplantation, vol. 30, no. 2, pp. 158–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Comoli, M. Cioni, A. Tagliamacco et al., “Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients,” American Journal of Transplantation, vol. 16, no. 7, pp. 2106–2116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Fichtner, C. Süsal, B. Höcker et al., “Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients,” Pediatric Nephrology, vol. 31, no. 7, pp. 1157–1166, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. S. Freitas, L. M. Rebellato, M. Ozawa et al., “The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes,” Transplantation, vol. 95, no. 9, pp. 1113–1119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Guidicelli, F. Guerville, S. Lepreux et al., “Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival,” Journal of the American Society of Nephrology, vol. 27, no. 2, pp. 615–625, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Loupy, C. Lefaucheur, D. Vernerey et al., “Complement-binding anti-HLA antibodies and kidney-allograft survival,” New England Journal of Medicine, vol. 369, no. 13, pp. 1215–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sicard, S. Ducreux, M. Rabeyrin et al., “Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 457–467, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Sutherland, G. Chen, F. A. Sequeira, C. D. Lou, S. R. Alexander, and D. B. Tyan, “Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss,” Pediatric Transplantation, vol. 16, no. 1, pp. 12–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Yabu, J. P. Higgins, G. Chen, F. Sequeira, S. Busque, and D. B. Tyan, “C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation,” Transplantation, vol. 91, no. 3, pp. 342–347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Lefaucheur, D. Viglietti, C. Bentlejewski et al., “IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury,” Journal of the American Society of Nephrology, vol. 27, no. 1, pp. 293–304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Schaub, G. Hönger, M. T. Koller, R. Liwski, and P. Amico, “Determinants of C1q binding in the single antigen bead assay,” Transplantation, vol. 98, no. 4, pp. 387–393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Zeevi, J. Lunz, B. Feingold et al., “Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients,” Journal of Heart and Lung Transplantation, vol. 32, no. 1, pp. 98–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. H. Ware, “The limitations of risk factors as prognostic tools,” The New England Journal of Medicine, vol. 355, no. 25, pp. 2615–2617, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. F. Polak, M. J. Pencina, K. M. Pencina, C. J. O'Donnell, P. A. Wolf, and R. B. D'Agostino Sr., “Carotid-wall intima-media thickness and cardiovascular events,” New England Journal of Medicine, vol. 365, no. 3, pp. 213–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Jary, D. Vernerey, T. Lecomte et al., “Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 3, pp. 603–612, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M. J. Pencina, R. B. D'Agostino Sr., R. B. D'Agostino Jr., and R. S. Vasan, “Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond,” Statistics in Medicine, vol. 27, no. 2, pp. 157–212, 2008. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  35. M. J. Pencina, R. B. D'Agostino, and E. W. Steyerberg, “Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers,” Statistics in Medicine, vol. 30, no. 1, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  36. M. J. Pencina and R. B. D'Agostino, “Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation,” Statistics in Medicine, vol. 23, no. 13, pp. 2109–2123, 2004. View at Google Scholar
  37. M. Karpinski, D. Rush, J. Jeffery et al., “Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2807–2814, 2001. View at Google Scholar · View at Scopus
  38. S. Mohan, A. Palanisamy, D. Tsapepas et al., “Donor-specific antibodies adversely affect kidney allograft outcomes,” Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 2061–2071, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. https://optn.transplant.hrsa.gov/governance/policies/.
  40. S. Heidt, M. D. Witvliet, G. W. Haasnoot, and F. H. J. Claas, “The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients,” Transplant Immunology, vol. 33, no. 2, pp. 51–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Süsal, D. L. Roelen, G. Fischer et al., “Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients,” Tissue Antigens, vol. 82, no. 2, pp. 83–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Wiebe, I. W. Gibson, T. D. Blydt-Hansen et al., “Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant,” American Journal of Transplantation, vol. 12, no. 5, pp. 1157–1167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Haas, R. A. Montgomery, D. L. Segev et al., “Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts,” American Journal of Transplantation, vol. 7, no. 3, pp. 576–585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Loupy, C. Suberbielle-Boissel, G. S. Hill et al., “Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies,” American Journal of Transplantation, vol. 9, no. 11, pp. 2561–2570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Loupy, D. Vernerey, C. Tinel et al., “Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts,” Journal of the American Society of Nephrology, vol. 26, no. 7, pp. 1721–1731, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Eskandary, G. Bond, N. Kozakowski et al., “Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study,” Transplantation, 2016. View at Publisher · View at Google Scholar
  47. J. M. Burns, L. D. Cornell, D. K. Perry et al., “Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation,” American Journal of Transplantation, vol. 8, no. 12, pp. 2684–2694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Archdeacon, M. Chan, C. Neuland et al., “Summary of FDA antibody-mediated rejection workshop,” American Journal of Transplantation, vol. 11, no. 5, pp. 896–906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Lefaucheur, A. Loupy, G. S. Hill et al., “Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1398–1406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Mizutani, P. Terasaki, E. Hamdani et al., “The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients,” American Journal of Transplantation, vol. 7, no. 4, pp. 1027–1031, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. C. Papadimitriou, C. B. Drachenberg, E. Ramos et al., “Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies,” Transplantation, vol. 95, no. 1, pp. 128–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. E. F. Reed, P. Rao, Z. Zhang et al., “Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA,” American Journal of Transplantation, vol. 13, no. 7, pp. 1859–1870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Earley, R. F. Vogt Jr., H. M. Shapiro et al., “Report from a workshop on multianalyte microsphere assays,” Cytometry, vol. 50, no. 5, pp. 239–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Waterboer, P. Sehr, and M. Pawlita, “Suppression of non-specific binding in serological Luminex assays,” Journal of Immunological Methods, vol. 309, no. 1-2, pp. 200–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. G. O'Leary, H. Kaneku, N. Banuelos, L. W. Jennings, G. B. Klintmalm, and P. I. Terasaki, “Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation,” American Journal of Transplantation, vol. 15, no. 4, pp. 1003–1013, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. J. D. Smith, M. W. Ibrahim, H. Newell et al., “Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation,” Journal of Heart and Lung Transplantation, vol. 33, no. 10, pp. 1074–1082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Bamoulid, A. Roodenburg, O. Staeck et al., “Clinical outcome of patients with de novo C1q-binding donor-specific HLA antibodies after renal transplantation,” Transplantation, 2016. View at Publisher · View at Google Scholar
  58. F. Nimmerjahn and J. V. Ravetch, “Immunology: divergent immunoglobulin G subclass activity through selective Fc receptor binding,” Science, vol. 310, no. 5753, pp. 1510–1512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M.-H. Tao, R. I. F. Smith, and S. L. Morrison, “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 661–667, 1993. View at Publisher · View at Google Scholar · View at Scopus
  60. M. C. Van Zelm, “B cells take their time: sequential IgG class switching over the course of an immune response,” Immunology and Cell Biology, vol. 92, no. 8, pp. 645–646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. M. J. Everly, L. M. Rebellato, C. E. Haisch et al., “Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients,” Transplantation, vol. 97, no. 5, pp. 494–501, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Khovanova, S. Daga, T. Shaikhina et al., “Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure,” Transplant International, vol. 28, no. 12, pp. 1405–1415, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Kimball, B. Wagner, and M. Burton, “Emergence of IgG3 alloantibody after renal transplantation associated with early graft failure,” Clinical Transplants, vol. 2006, pp. 526–528, 2006. View at Google Scholar · View at Scopus
  64. H. Kaneku, J. G. O'Leary, M. Taniguchi, B. M. Susskind, P. I. Terasaki, and G. B. Klintmalm, “Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation,” Liver Transplantation, vol. 18, no. 8, pp. 984–992, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. D. M. Eddy, J. Adler, B. Patterson, D. Lucas, K. A. Smith, and M. Morris, “Individualized guidelines: the potential for increasing quality and reducing costs,” Annals of Internal Medicine, vol. 154, no. 9, pp. 627–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Wagner, E. M. Balk, D. M. Kent, B. L. Kasiske, and H. Ekberg, “Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation,” American Journal of Transplantation, vol. 9, no. 10, pp. 2217–2222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. D. M. Kent and R. A. Hayward, “Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification,” Journal of the American Medical Association, vol. 298, no. 10, pp. 1209–1212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Kamisawa, Y. Zen, S. Pillai, and J. H. Stone, “IgG4-related disease,” The Lancet, vol. 385, no. 9976, pp. 1460–1471, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. L. D. Cornell, C. A. Schinstock, M. J. Gandhi, W. K. Kremers, and M. D. Stegall, “Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year,” American Journal of Transplantation, vol. 15, no. 5, pp. 1293–1302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. M. D. Stegall, T. Diwan, S. Raghavaiah et al., “Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients,” American Journal of Transplantation, vol. 11, no. 11, pp. 2405–2413, 2011. View at Publisher · View at Google Scholar
  71. D. Viglietti, C. Gosset, A. Loupy et al., “C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study,” American Journal of Transplantation, vol. 16, no. 5, pp. 1596–1603, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. R. A. Montgomery, B. J. Orandi, L. Racusen et al., “Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study,” American Journal of Transplantation, vol. 16, no. 12, pp. 3468–3478, 2016. View at Publisher · View at Google Scholar